Skip to main content

PBE

ETF

PBE

ETF
—
—

Performance overview

PBE Price
Price Chart

Forward-looking statistics

Beta
0.91
Risk
18.35%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Fund Profile

The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Fund info

The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Investing methodPassively Managed
DiversifiedNo
Expense ratio0.50%
Asset classUnknown

Company info

Sector—
Industry—
Website—
AUM—

Security info

ExchangeNyse American
Type of shareN/A
Earnings per share (EPS)—
Dividend per share$0.14
Revenue per share—
Avg trading volume (30 day)$407K
Avg trading volume (10 day)$444K
Put-call ratioN/A

Macro factor sensitivity

Growth+0.1
Credit+4.3
Liquidity+0.7
Inflation-2.9
Commodities-0.4
Interest Rates-1.5

Upcoming events

Next earnings day—
Next dividend day—
Ex. dividend dayMarch 24, 2025

News

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

Launched on 06/23/2005, the Invesco Biotechnology & Genome ETF (PBE) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.

Zacks Investment Research (May 27, 2025)
5 Top ETFs With Exposure To Biogen

For the first time in 18 years, there was a new treatment for Alzheimer's Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that can reduce the clinical decline of dementia.

Benzinga (June 7, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free